Mealey's (August 24, 2018, 11:41 AM EDT) -- BOSTON — Allegations by two putative classes that Novartis Pharmaceuticals Corp. fraudulently procured a patent for the leukemia drug Gleevec are not plausible, and the drug maker thus cannot be subject to antitrust scrutiny, the First Circuit U.S. Court of Appeals ruled Aug. 21 (United Food and Commercial Workers Unions and Employers Midwest Health Benefits Fund, et al. v. Novartis Pharmaceuticals Corporation, Nos. 17-1714, -1776, 1st Cir., 2018 U.S. App. LEXIS 23284)....